Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xalacom versus Cosopt in open-angle glaucoma or ocular hypertension
2005-001128-35Phase 4Completed
- Sponsor
- Pfizer
- Start
- May 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of timolol and dorzolamide in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Pfizer. Primary endpoint: Mean diurnal intraocular pressure reduction from baseline to Week 12. Started May 2005; status: completed.
02
Drugs
timololdorzolamide
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on 2005-001128-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001128-35.